Table 1 Patient characteristics at baseline
Intervention group (n = 30) | Control group (n = 30) | ||||
|---|---|---|---|---|---|
n | % | n | % | ||
Age (years) | |||||
Mean (SD) | 61.3 +/− 10.1 | 64.1 +/− 10.9 | |||
Gender | |||||
Male | 14 | 46.7 | 19 | 63.3 | |
Female | 16 | 53.3 | 11 | 36.7 | |
Karnofsky-index (median, range) | 80 (70–100) | 80 (70–100) | |||
Primary site | |||||
Lung cancer | 12 | 9.2 | 8 | 26.6 | |
Breast cancer | 5 | 16.7 | 6 | 20.1 | |
Prostate cancer | 5 | 16.7 | 9 | 30.1 | |
Melanoma | 1 | 3.3 | 1 | 3.3 | |
Renal cancer | 1 | 3.3 | 2 | 6.7 | |
Other | 6 | 20.1 | 4 | 13.4 | |
Localization metastases | |||||
Thoracic | 17 | 56.7 | 14 | 46.7 | |
Lumbar | 9 | 30.0 | 13 | 43.3 | |
Thoracic and lumbar | 2 | 6.7 | 2 | 6.7 | |
Sacrum | 2 | 6.7 | 1 | 3.3 | |
Number metastases | |||||
Mean (range) | 1.4 (2–4) | 1.7 (1–5) | |||
Solitary | 22 | 73.3 | 18 | 60.0 | |
Multiple | 8 | 26.7 | 12 | 40.0 | |
Type of metastases | |||||
osteoblast | 9 | 30.0 | 10 | 33.3 | |
osteolytic | 21 | 70.0 | 20 | 66.7 | |
Size of metastasis | |||||
Mean (SD) | 318.6 +/− 230.0 | 380.7 +/− 193.6 | |||
Distant metastases at baseline | |||||
Visceral | 12 | 40.0 | 5 | 16.7 | |
brain | 3 | 10.0 | 3 | 10.0 | |
lung | 7 | 23.3 | 4 | 13.3 | |
tissue | 8 | 26.7 | 6 | 20.0 | |
Hormonotherapy | 10 | 33.3 | 16 | 53.3 | |
Immunotherapy | 7 | 23.3 | 5 | 16.7 | |
Chemotherapy | 25 | 83.3 | 20 | 66.7 | |
Previous SRE | 9 | 30.0 | 13 | 43.3 | |